Glepaglutide FDA Approval Status
Last updated by Judith Stewart, BPharm on Dec 20, 2024.
FDA Approved: No
Generic name: glepaglutide
Company: Zealand Pharma A/S
Treatment for: Short Bowel Syndrome
Glepaglutide is a long-acting glucagon-like peptide-2 (GLP-2) analog in development for the treatment of short bowel syndrome.
- Short bowel syndrome (SBS) is a condition that develops when the small intestine is shortened or damaged so cannot absorb enough nutrients from food. Patients with SBS are dependent on receiving fluids and nutrition parenterally.
- Glepaglutide is a GLP-2 analog that works by improving intestinal absorptive function to reduce or eliminate the need for parenteral support in SBS patients.
- Glepaglutide is being developed as a liquid product in an autoinjector designed for twice weekly dosing by subcutaneous administration.
- The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for glepaglutide for the treatment of SBS.
Development timeline for glepaglutide
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.